Inclusion Criteria:

• Have a biopsy confirmed diagnosis thereby providing histological diagnosis of a solid tumor malignancy.
• Have been offered all standard or approved therapies for which they would be considered eligible and have specifically declined or decided to postpone.
• Have solid tumors that can be measured on physical examination or by radiographic imaging studies.
• Be 18 years old or older.
• Have an ECOG performance study of 0, 1 or 2.
• Be able to give informed consent.
• Have recovered from any previous therapy side effects or toxicities prior to initiating protocol study infusions.
• Have a life expectancy of more than 12 weeks.
• Female subjects of childbearing potential must have a negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
• Male and female subjects of reproductive potential must agree to use measures (e.g., condoms or birth control pills) to avoid pregnancy throughout the study and for 3 months following discontinuation of the study drug.
• Organ function characterized by </= Grade 1 scores defined by CTCAE v3.0.

• Laboratory values meeting the following criteria:

  • Hemoglobin >/= 10.0 gm/dL
  • Absolute neutrophil count > 1500/mm3
  • White blood cell count > 3000/mm3
  • Platelet count >/= 100,000/mm3
  • PT/PTT < 1.5 times the upper limit of normal
  • LDH < 3 times the upper limit of normal but without concomitant elevations in any of the following: PT, PTT, or D-dimer or clinical evidence of Disseminated Intravascular Coagulation
  • Total bilirubin </= 1.5 times the upper limit of normal
  • AST and ALT </= 2.5 times the upper limit of normal
  • Creatinine </= 1.5 mg/dL or creatinine clearance >/= 50 ml/minute

Exclusion Criteria:

• Have hematological malignancy
• Are pregnant or lactating women
• Have signs and symptoms consistent with an active infection
• Fever (> 38.1oC)
• Treated with antibiotics for infection within one-week prior to study entry
• Known HIV infection
• Have any history of psychiatric disorders that would interfere with informed consent or follow-up.
• Have any other concurrent disease that, in the judgment of the investigator, would contraindicate the administration of study drug or interfere with the study evaluations.
• Have diastolic blood pressure of > 90 mm Hg resting at baseline despite medication. (Acceptable if on hypertensive medication and diastolic blood pressure is </= 90 mm Hg.)
• Unfavorable results of stress echocardiogram after consultation with cardiologist.
• Have known cardiac disease, or a history of cardiac disease.

• Had within six months prior to enrollment any of the following:

  • Cerebrovascular accident
  • Uncontrolled congestive heart failure (dyspnea on minimal exertion or while supine)
  • Unstable angina (chest pain greater than three times weekly while on therapy)
• Have significant baseline neuropathies (>/= grade 2 based upon CTCAE v 3.0).
• Requiring renal dialysis.
• Receiving systemic steroids or other chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine) within 30 days prior to study entry
• Receiving hematopoietic growth factors
• Receiving anticoagulants other than to maintain patency of venous access lines
• Received an investigational drug within 30 days prior to study entry
• Received radiation treatment < 4 weeks prior to study entry
• Had prior exposure to gene vector delivery products
• Received treatment with chemotherapeutic agents < 4 weeks prior to study entry except for mitomycin C or nitrosurea where subjects who received mitomycin C or nitrosoureas < 6 weeks prior to study entry are not eligible.